Laura M Dember, MD
Dr. Dember is a nephrologist and clinical investigator with a major focus on interventions to improve outcomes in end-stage kidney disease. She is a national leader for multicenter clinical trials and observational cohort studies including the Dialysis Access Consortium trials, the Hemodialysis Fistula Maturation Study, and the HiLo trial, all funded by the National Institutes of Health. She was the Principal Investigator for the Time to Reduce Mortality in End-Stage Renal Disease Trial (TiME), a large cluster-randomized pragmatic trial conducted in partnership with two large dialysis provider organizations as one of the initial trials of the NIH Health Care Systems Research Collaboratory. She is the Principal Investigator of the Data Coordinating Center for the NIDDK Hemodialysis Novel Therapies Consortium, Prinicipal Investigator of the Scientific and Data Research Center for the NIH HEAL Initiative HOPE Trial, and a member of the Scientific and Data Coordinating Center for the NIDDK Chronic Renal Insufficiency Cohort Study (CRIC). Dr. Dember has led projects for the Kidney Health Initiative, a public-private partnership between the American Society of Nephrology and the FDA to facilitate innovation in kidney disease treatments, is Deputy Editor for the American Journal of Kidney Diseases, and is the Director for the Penn CCEB Certificate Program in Clinical Research. Dr. Dember is a graduate of Yale University School of Medicine and completed her internal medicine residency training at the University of Pennsylvania and nephrology fellowship training at Penn and the Brigham and Women’s Hospital.
Kidney disease, Dialysis, Amyloidosis
Clinical Trials, Pragmatic Trials, Cohort Studies, Embedded Research, Real-World Data, Rare Disease Research